benmelstobart + anlotinib + etoposide

Benmelstobart + anlotinib + etoposide is a combination therapeutic regimen primarily used as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The regimen consists of **benmelstobart**, a humanized IgG1 monoclonal antibody that acts as a programmed death-ligand 1 (PD-L1) inhibitor; **anlotinib**, a multi-target small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-4), platelet-derived growth factor receptors (PDGFR α/β), and c-Kit; and **etoposide**, a standard cytotoxic chemotherapy agent that inhibits DNA topoisomerase II. This triplet therapy was evaluated in the pivotal Phase 3 ETER701 trial, which demonstrated a significant improvement in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy. Benmelstobart was developed by Chia Tai Tianqing Pharmaceutical Group and received approval from China's NMPA in May 2024 for use in this combination for first-line SCLC.

Other names

benmelstobart combined with anlotinib and etoposide